BioCentury
ARTICLE | Company News

Pfizer buying AZ's small molecule anti-infectives business

August 24, 2016 7:00 AM UTC

Pfizer Inc. (NYSE:PFE) is acquiring the small molecule anti-infectives business of AstraZeneca plc (LSE:AZN; NYSE:AZN) for $550 million in cash up front and $175 million due in January 2019. The unit includes approved drugs Zavicefta ceftazidime/avibactam, Zinforo ceftaroline fosamil and Merrem/Meronem meropenam, as well as a pair of Phase II candidates.

AstraZeneca is eligible for $250 million in milestones and $600 million in "sales-related payments," plus tiered royalties on sales of Zavicefta and pipeline candidate ATM-AVI. ...